CrowdStrike Just Had Its Best Quarter Ever, and I'm Not Buying the Stock at 43 Times Revenue

CrowStrike reported record fiscal Q2 net new ARR of $332.8M (+51% YoY) and total ARR of $5.84B (+25%), alongside 26% YoY revenue growth to $1.47B and $377.4M free cash flow (+33%). Management raised its outlook to ~ $6.0B fiscal 2027 revenue and lifted net new ARR growth to 34% (+630 bps at the midpoint), with shares jumping >20% to about $228 after the release. Despite the strong results, the article flags valuation risk at ~43x trailing sales (~39x expected sales), implying the current multiple already prices continued outperformance.

Analysis

CRWD’s print is constructive for the cybersecurity complex, but the market mechanism is different from the operating story: this is now a multiple-duration trade, not a fundamental recovery trade. The quarter validates demand durability and should keep budget dollars flowing toward platform vendors, but it also raises the bar for every peer to prove they can grow without paying up in discounts or bundling.

The first-order winner is sentiment across the sector; the second-order winner may be lower-multiple names that can absorb incremental cyber spend without requiring CRWD-like perfection. If buyers rotate toward platform consolidation, PANW and even FTNT can benefit from “good enough” growth at cheaper valuations, while CRWD becomes more exposed to any deceleration in net-new ARR or a normalizing pipeline-to-booking conversion rate. The balance sheet is not the issue here; equity duration is.

Over the next 1-3 months, the key catalyst is not another beat but whether management can re-accelerate again off an already elevated base. If net new ARR slips back toward the low-20s and the stock holds a high-30s/40x sales multiple, valuation compression can overwhelm continued outperformance. Contrarian risk: the market may be underestimating how long CRWD can compound as a security operating system, but the burden of proof is now on sustained >30% ARR growth for multiple quarters, not a single quarter.

Key Decisions for Investors

• Prefer to express a bearish view with options, not outright short stock: buy a 3-6 month CRWD bear call spread after any failed re-test of post-earnings highs; target limited downside with defined risk because momentum can persist longer than fundamentals.
• Pair trade: short CRWD vs long a cheaper cyber basket weighted to PANW/FTNT over the next 1-3 months; thesis is valuation mean reversion, not sector collapse. Cover if CRWD next-quarter net new ARR stays above ~30% and the stock re-rates to a structurally higher multiple.
• If owning cyber exposure, rotate incremental capital from CRWD into sector proxies or lower-multiple platform names rather than chasing the highest-quality/most expensive single name; the setup favors breadth over concentration.
• Set a falsifier alert: if CRWD guides another quarter of >30% net new ARR and lifts FY27 revenue again, abandon the short-valuation thesis and respect that the market is willing to pay for a longer growth runway.